BioLife Solutions Announces Executive Appointments to Support Integration of Acquired Companies

BOTHELL, Wash., Dec. 2, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced several executive appointments to further support the integration of Astero Bio, SAVSU Technologies, and Custom Biogenic Systems, three companies acquired during 2019.

Cell and gene therapy tools. (PRNewsfoto/BioLife Solutions, Inc.)

Aby J. Mathew, PhD, former Senior Vice President and Chief Technology Officer has been appointed Executive Vice President and Chief Scientific Officer.  In this role, Dr. Mathew is responsible for integrating the value propositions of the acquired automated thaw, cold chain management and advanced freezer products into the Company's ongoing market education commitment to best bioproduction practices for cell and gene therapies.

Roderick de Greef, the Company's Chief Financial Officer, has added the position of Chief Operating Officer. In his expanded role, de Greef is responsible for ensuring financial visibility, and driving manufacturing and operational performance and efficiencies across the enterprise.

Karen Foster, former Vice President, Media Operations, has been appointed Chief Quality Officer. In her expanded role, Foster will utilize her many years of successful implementation of continuous quality improvement initiatives to ensure a consistent customer-focused, data driven quality culture is fostered and maintained for all product lines in BioLife's expanded bioproduction tools portfolio.

Todd Berard, former Vice President, Marketing, has been appointed Chief Marketing Officer, with global marketing responsibilities including the integration and harmonization of all product brands across the portfolio.

Jim Mathers, former Vice President, Sales, has been appointed Chief Revenue Officer. He is responsible for driving the worldwide direct and indirect selling organizations to meet the Company's global revenue targets.

Mike Rice, BioLife President & CEO, commented, "We are critically focused on successfully integrating Astero Bio, SAVSU and Custom Biogenic Systems products into our portfolio and on ensuring our long-standing, customer-recognized commitment to quality is maintained and continually improved across the enterprise.  I look forward to working with our executive management team to build BioLife into a much larger, efficiently managed organization."

About BioLife Solutions

BioLife Solutions is a leading supplier of cell and gene therapy bioproduction tools. Our proprietary CryoStor® freeze media and HypoThermosol® shipping and storage media are highly valued in the regenerative medicine, biobanking and drug discovery markets. These biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. Our ThawSTAR® family of automated cell thawing products and evo® cold chain management system can mitigate economic risk for cell and gene therapy developers by reducing the potential of administering a non-viable dose. For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

Media & Investor Relations
Roderick de Greef
Chief Financial Officer
(425) 686-6002
rdegreef@biolifesolutions.com

 

SOURCE BioLife Solutions, Inc.

We believe the promise of cell and gene therapies starts with the integrity of a single cell

Advancing the future of cell and gene therapy

The human body can heal itself. Cell and gene therapies are designed to augment the patient’s ability to fight disease but only if the living cells behind those therapies remain viable and functional throughout the production processes. At BioLife Solutions, our mission is to protect the integrity of cells and provide trusted tools, services, and expertise that can enable our customers to advance the development and delivery of cell and gene therapies. We believe the future of cell and gene therapies hinges on the integrity of every single cell and we are here to protect that promise.

We understand the technical demands of bioprocessing in this field, and our advanced biopreservation expertise, cell culture optimization products, innovative storage systems, and closed-system manufacturing solutions are designed to enhance process efficiency, maintain cellular viability, and ensure reproducibility at every stage. Whether scaling up from R&D, navigating clinical trials or optimizing cryopreservation protocols for commercial production, we provide the tools and experience to streamline your workflow and safeguard your therapies.

Work with experts who understand your biopreservation challenges

Notch-Right-25px
Notch-Bottom-25px

Collaborative and comprehensive CDMO support

At BioLife Solutions, we partner with leading contract development and manufacturing organizations (CDMOs) to enhance their biopreservation and cell processing capabilities. By providing advanced tools, regulatory support, and process optimization strategies, we empower CDMOs to better serve therapy developers, ensuring quality, consistency, and scalability in cell therapy manufacturing.

Regulatory
readiness

Navigating the complex regulatory landscape of cell and gene therapy requires a proactive approach. BioLife Solutions offers experienced regulatory support to help prepare your biopreservation and cell processing methods to meet global standards. From IND and BLA submissions to compliance with GMP, FDA, and EMA guidelines, our solutions help streamline approval pathways.

Notch-Left-25px
Notch-Bottom-25px

STORE

CellSeal®
CryoCase

Alleviate CGT container challenges like fracture risk, bag burping or high rates of particulates

Notch-Right-25px
Notch-Bottom-25px

Data-driven
decision making

Stay ahead with our comprehensive Evidence Library, a curated collection of scientific publications, white papers, and case studies demonstrating the efficacy of BioLife Solutions’ technologies. Access peer-reviewed research, real-world application data, and expert insights to support your bioprocessing and regulatory strategies.

Insights

May 21, 2025

Designing the Ideal Cryostorage Container for CGT

April 18, 2025

The Cell Summit ’25: A Must-Attend Event for Innovators in Cell & Gene Therapy

March 27, 2025

Optimizing Biopreservation Strategies for Apheresis-Derived Cells in Immunotherapeutic Applications

February 19, 2025

How to prepare early for regulatory submissions from IND to BLA

Preserve, protect and expand cell performance

Mastering
Biopreservation

Ensure Regulatory Submission Readiness

Automate & Close
CGT Processes

Protect & Expand
Cell Performance